These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6702493)

  • 1. Treatment of digital vasospastic disease with the calcium-entry blocker nifedipine.
    Nilsson H; Jonasson T; Ringqvist I
    Acta Med Scand; 1984; 215(2):135-9. PubMed ID: 6702493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the calcium-entry blocker nifedipine on cold-induced digital vasospasm. A double-blind crossover study versus placebo.
    Nilsson H; Jonason T; Leppert J; Ringqvist I
    Acta Med Scand; 1987; 221(1):53-60. PubMed ID: 3551507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium entry blocking agents in digital vasospasm (Raynaud's phenomenon).
    Kahan A; Weber S; Amor B; Menkes CJ; Saporta L; Hodara M; Guerin F; Degeorges M
    Eur Heart J; 1983 May; 4 Suppl C():123-9. PubMed ID: 6352267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of calcium antagonists in the treatment of ocular circulation symptoms in the framework of a vasospastic syndrome].
    Gasser P; Flammer J; Mahler F
    Schweiz Med Wochenschr; 1988 Feb; 118(6):201-2. PubMed ID: 3363311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nifedipine as a therapeutic modality for Raynaud's phenomenon.
    Winston EL; Pariser KM; Miller KB; Salem DN; Creager MA
    Arthritis Rheum; 1983 Oct; 26(10):1177-80. PubMed ID: 6626276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Raynaud's phenomenon with calcium channel blockers.
    Smith CR; Rodeheffer RJ
    Am J Med; 1985 Feb; 78(2B):39-42. PubMed ID: 3976694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digital and radial artery blood flow in patients with Raynaud's phenomenon in response to nifedipine.
    Morgan RH; Psaila JV; Davies WT; Carolan G; Woodcock JP
    Eur J Vasc Surg; 1987 Dec; 1(6):403-8. PubMed ID: 3503035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon].
    Kahan A; Weber S; Amor B; Saporta L; Hodara M; Degeorges M
    Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):337-43. PubMed ID: 6285445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reaction of capillary blood cell velocity in nailfold capillaries to nifedipine and ketanserin in patients with vasospastic disease.
    Gasser P
    J Int Med Res; 1991; 19(1):24-31. PubMed ID: 2019313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial.
    Wise RA; Malamet R; Wigley FM
    J Rheumatol; 1987 Apr; 14(2):278-83. PubMed ID: 3298649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational use of calcium-channel antagonists in Raynaud's phenomenon.
    Sturgill MG; Seibold JR
    Curr Opin Rheumatol; 1998 Nov; 10(6):584-8. PubMed ID: 9812220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of digital blood pressure to cold provocation in cases with Raynaud phenomena.
    Thulesius O; Brubakk A; Berlin E
    Angiology; 1981 Feb; 32(2):113-8. PubMed ID: 7212385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.
    Ettinger WH; Wise RA; Schaffhauser D; Wigley FM
    Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and function of small arteries of essential hypertensive patients following chronic treatment with once-a-day nifedipine.
    Schiffrin EL
    Cardiology; 1997; 88 Suppl 3():20-6. PubMed ID: 9397289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of treatment efficacy of Raynaud phenomenon by digital blood pressure response to cooling. Raynaud's Treatment Study Investigators.
    Maricq HR; Jennings JR; Valter I; Frederick M; Thompson B; Smith EA; Hill R;
    Vasc Med; 2000; 5(3):135-40. PubMed ID: 11104295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifedipine in the treatment of Raynaud's syndrome.
    Aldoori M; Campbell WB; Dieppe PA
    Cardiovasc Res; 1986 Jun; 20(6):466-70. PubMed ID: 3536108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.
    White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT
    Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.